301 related articles for article (PubMed ID: 35332124)
21. Recent advances in tumor microenvironment-targeted nanomedicine delivery approaches to overcome limitations of immune checkpoint blockade-based immunotherapy.
Kim J; Hong J; Lee J; Fakhraei Lahiji S; Kim YH
J Control Release; 2021 Apr; 332():109-126. PubMed ID: 33571549
[TBL] [Abstract][Full Text] [Related]
22. Synthetic Immunology: Hacking Immune Cells to Expand Their Therapeutic Capabilities.
Roybal KT; Lim WA
Annu Rev Immunol; 2017 Apr; 35():229-253. PubMed ID: 28446063
[TBL] [Abstract][Full Text] [Related]
23. Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium.
Guo Y; Chen Y; Liu X; Min JJ; Tan W; Zheng JH
Cancer Lett; 2020 Jan; 469():102-110. PubMed ID: 31666180
[TBL] [Abstract][Full Text] [Related]
24. Bacteria-cancer interactions: bacteria-based cancer therapy.
Duong MT; Qin Y; You SH; Min JJ
Exp Mol Med; 2019 Dec; 51(12):1-15. PubMed ID: 31827064
[TBL] [Abstract][Full Text] [Related]
25. Thermal Control of Engineered T-cells.
Abedi MH; Lee J; Piraner DI; Shapiro MG
ACS Synth Biol; 2020 Aug; 9(8):1941-1950. PubMed ID: 32786924
[TBL] [Abstract][Full Text] [Related]
26. Engineered probiotics for local tumor delivery of checkpoint blockade nanobodies.
Gurbatri CR; Lia I; Vincent R; Coker C; Castro S; Treuting PM; Hinchliffe TE; Arpaia N; Danino T
Sci Transl Med; 2020 Feb; 12(530):. PubMed ID: 32051224
[TBL] [Abstract][Full Text] [Related]
27. Bacterially mediated drug delivery and therapeutics: Strategies and advancements.
Wu L; Bao F; Li L; Yin X; Hua Z
Adv Drug Deliv Rev; 2022 Aug; 187():114363. PubMed ID: 35649449
[TBL] [Abstract][Full Text] [Related]
28. Genetically engineered monoclonal antibodies for direct anti-neoplastic treatment and cancer cell specific delivery of chemotherapeutic agents.
Bodey B; Bodey B; Siegel SE; Kaiser HE
Curr Pharm Des; 2000 Feb; 6(3):261-76. PubMed ID: 10637379
[TBL] [Abstract][Full Text] [Related]
29. Developing a new class of engineered live bacterial therapeutics to treat human diseases.
Charbonneau MR; Isabella VM; Li N; Kurtz CB
Nat Commun; 2020 Apr; 11(1):1738. PubMed ID: 32269218
[TBL] [Abstract][Full Text] [Related]
30. Tumor-Targeted Nanomedicine for Immunotherapy.
Cabral H; Kinoh H; Kataoka K
Acc Chem Res; 2020 Dec; 53(12):2765-2776. PubMed ID: 33161717
[TBL] [Abstract][Full Text] [Related]
31. Targeting Natural Killer Cells for Tumor Immunotherapy.
Zhang C; Hu Y; Shi C
Front Immunol; 2020; 11():60. PubMed ID: 32140153
[TBL] [Abstract][Full Text] [Related]
32. Bacteria and bacterial derivatives as delivery carriers for immunotherapy.
Kang SR; Nguyen DH; Yoo SW; Min JJ
Adv Drug Deliv Rev; 2022 Feb; 181():114085. PubMed ID: 34933064
[TBL] [Abstract][Full Text] [Related]
33. Targeting hypoxia in the tumor microenvironment: a potential strategy to improve cancer immunotherapy.
Wang B; Zhao Q; Zhang Y; Liu Z; Zheng Z; Liu S; Meng L; Xin Y; Jiang X
J Exp Clin Cancer Res; 2021 Jan; 40(1):24. PubMed ID: 33422072
[TBL] [Abstract][Full Text] [Related]
34. Synthetic Biology Approaches in The Development of Engineered Therapeutic Microbes.
Kang M; Choe D; Kim K; Cho BK; Cho S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33228099
[TBL] [Abstract][Full Text] [Related]
35. Two-step enhanced cancer immunotherapy with engineered
Zheng JH; Nguyen VH; Jiang SN; Park SH; Tan W; Hong SH; Shin MG; Chung IJ; Hong Y; Bom HS; Choy HE; Lee SE; Rhee JH; Min JJ
Sci Transl Med; 2017 Feb; 9(376):. PubMed ID: 28179508
[TBL] [Abstract][Full Text] [Related]
36. Prospects for personalized combination immunotherapy for solid tumors based on adoptive cell therapies and immune checkpoint blockade therapies.
Kato D; Yaguchi T; Iwata T; Morii K; Nakagawa T; Nishimura R; Kawakami Y
Nihon Rinsho Meneki Gakkai Kaishi; 2017; 40(1):68-77. PubMed ID: 28539557
[TBL] [Abstract][Full Text] [Related]
37. Upconversion Optogenetic Engineered Bacteria System for Time-Resolved Imaging Diagnosis and Light-Controlled Cancer Therapy.
Zhang Y; Xue X; Fang M; Pang G; Xing Y; Zhang X; Li L; Chen Q; Wang Y; Chang J; Zhao P; Wang H
ACS Appl Mater Interfaces; 2022 Oct; 14(41):46351-46361. PubMed ID: 36201723
[TBL] [Abstract][Full Text] [Related]
38. The potential use of theranostic bacteria in cancer.
Azizian K; Pustokhina I; Ghanavati R; Hamblin MR; Amini A; Kouhsari E
J Cell Physiol; 2021 Jun; 236(6):4184-4194. PubMed ID: 33174198
[TBL] [Abstract][Full Text] [Related]
39. Current Status and Future Directions of Bacteria-Based Immunotherapy.
Tang Q; Peng X; Xu B; Zhou X; Chen J; Cheng L
Front Immunol; 2022; 13():911783. PubMed ID: 35757741
[TBL] [Abstract][Full Text] [Related]
40. Engineering Newcastle Disease Virus as an Oncolytic Vector for Intratumoral Delivery of Immune Checkpoint Inhibitors and Immunocytokines.
Vijayakumar G; McCroskery S; Palese P
J Virol; 2020 Jan; 94(3):. PubMed ID: 31694938
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
